Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection
Agnès Girard(Pfizer (United States)), James A. Retsema(Pfizer (United States)), D Girard(Pfizer (United States))
Cited by 73
Related Papers
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
|Antimicrobial Agents and Chemotherapy|1987|461
CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization
|Antimicrobial Agents and Chemotherapy|1978|397
<b>Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, <i>mefA</i>, from <i>Streptococcus pyogenes</i></b>
|Molecular Microbiology|1996|360
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
|Antimicrobial Agents and Chemotherapy|1987|323